HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roger L Whiting Selected Research

trazpiroben

10/2021Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis.
1/2021Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roger L Whiting Research Topics

Disease

2Gastroparesis
10/2021 - 01/2021
1Vomiting
10/2021
1Cardiac Arrhythmias (Arrythmia)
10/2021

Drug/Important Bio-Agent (IBA)

2trazpirobenIBA
10/2021 - 01/2021
2Dopamine (Intropin)FDA LinkGeneric
10/2021 - 01/2021
1Domperidone (Domperidon)IBA
10/2021
1Metoclopramide (Reglan)FDA LinkGeneric
10/2021
1ProlactinIBA
10/2021
1ApomorphineFDA Link
10/2021

Therapy/Procedure

1Therapeutics
10/2021